微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 83.81% | -2.15% | -0.06% | 14/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 83.86% | -0.41% | 1.61% | 15/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 82.53% | -3.22% | -1.2% | 15/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 83.53% | -5.82% | -2.47% | 15/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 85.65% | -3.31% | 1.72% | 11/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 84.2% | -5.32% | -1.27% | 12/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 85.28% | -3.04% | -3.85% | 15/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 88.69% | -3.84% | 0.13% | 8/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 88.58% | -4.53% | -0.39% | 7/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 88.93% | -4.07% | 1.11% | 8/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 87.95% | -6.07% | -4.64% | 10/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 92.23% | -0.37% | -0.59% | 9/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 92.78% | -0.23% | 0.08% | 5/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 92.7% | -0.19% | -1% | 5/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 93.64% | 0.81% | 1.15% | 3/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 92.57% | -0.7% | -0.45% | 4/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 92.99% | -0.58% | 0.12% | 4/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 92.88% | -1.67% | 0% | 2/160 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 92.88% | -1.27% | -0.37% | 3/160 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 93.23% | -1.2% | -0.33% | 2/160 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 93.54% | -2.03% | -0.97% | 2/160 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 94.46% | -1.1% | 0.4% | 2/160 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 94.08% | -1.53% | -0.3% | 2/160 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 94.36% | -1.44% | -1.16% | 2/160 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 95.47% | -0.35% | -0.03% | 1/160 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 95.51% | -0.07% | -0.04% | 1/160 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 95.54% | -0.36% | -0.21% | 1/160 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 95.74% | -1.12% | -0.07% | 1/160 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 95.81% | -1.24% | 0.24% | 1/160 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 95.58% | -1.48% | -0.32% | 1/160 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 95.89% | 2% | -0.97% | 1/160 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 96.83% | -0.12% | -0.18% | 2/160 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 97.01% | 2% | -0.01% | 1/160 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 97.02% | 2% | 0.07% | 1/160 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2015-12-31 | 96.95% | 0.43% | 0.43% | 1/160 | 46.24% | 贝达药业 | 97.01% | 行业排名> |